BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28385379)

  • 1. Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.
    McLaren PJ; Barnes AP; Terrell WZ; Vaccaro GM; Wiedrick J; Hunter JG; Dolan JP
    Am J Surg; 2017 May; 213(5):915-920. PubMed ID: 28385379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
    Tanaka K; Otake K; Mohri Y; Ohi M; Yokoe T; Toiyama Y; Miki C; Tonouchi H; Kusunoki M
    Oncol Rep; 2009 Jun; 21(6):1489-94. PubMed ID: 19424628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma.
    Skinner HD; Lee JH; Bhutani MS; Weston B; Hofstetter W; Komaki R; Shiozaki H; Wadhwa R; Sudo K; Elimova E; Song S; Ye Y; Huang M; Ajani J; Wu X
    Cancer; 2014 Dec; 120(23):3635-41. PubMed ID: 25091571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing.
    Chiam K; Mayne GC; Watson DI; Woodman RJ; Bright TF; Michael MZ; Karapetis CS; Irvine T; Phillips WA; Hummel R; Wang T; Pimlott LK; Marri S; Astill DS; Ruszkiewicz AR; Thompson SK; Hussey DJ
    Ann Surg Oncol; 2018 Sep; 25(9):2731-2738. PubMed ID: 29987600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
    Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
    Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
    Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
    Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
    Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
    Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
    Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
    J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
    Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
    Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.
    Haisley KR; Laird AE; Nabavizadeh N; Gatter KM; Holland JM; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    JAMA Surg; 2016 Nov; 151(11):e162743. PubMed ID: 27627765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes associated with surgery for T4 esophageal cancer.
    Pimiento JM; Weber J; Hoffe SE; Shridhar R; Almhanna K; Vignesh S; Karl RC; Meredith KL
    Ann Surg Oncol; 2013 Aug; 20(8):2706-12. PubMed ID: 23504118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
    Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
    Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
    Duong C; Greenawalt DM; Kowalczyk A; Ciavarella ML; Raskutti G; Murray WK; Phillips WA; Thomas RJ
    Ann Surg Oncol; 2007 Dec; 14(12):3602-9. PubMed ID: 17896157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?
    Voncken FE; Jiang H; Kim J; Guindi M; Brierley J; Knox J; Liu G; Horgan AM; Lister J; Darling G; Metser U; Wong RK
    Dis Esophagus; 2014 Aug; 27(6):552-9. PubMed ID: 23121504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
    Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.